Portal hypertension in cirrhosis: Pathophysiological mechanisms and therapy
- PMID: 34337369
- PMCID: PMC8318926
- DOI: 10.1016/j.jhepr.2021.100316
Portal hypertension in cirrhosis: Pathophysiological mechanisms and therapy
Abstract
Portal hypertension, defined as increased pressure in the portal vein, develops as a consequence of increased intrahepatic vascular resistance due to the dysregulation of liver sinusoidal endothelial cells (LSECs) and hepatic stellate cells (HSCs), frequently arising from chronic liver diseases. Extrahepatic haemodynamic changes contribute to the aggravation of portal hypertension. The pathogenic complexity of portal hypertension and the unsuccessful translation of preclinical studies have impeded the development of effective therapeutics for patients with cirrhosis, while counteracting hepatic and extrahepatic mechanisms also pose a major obstacle to effective treatment. In this review article, we will discuss the following topics: i) cellular and molecular mechanisms of portal hypertension, focusing on dysregulation of LSECs, HSCs and hepatic microvascular thrombosis, as well as changes in the extrahepatic vasculature, since these are the major contributors to portal hypertension; ii) translational/clinical advances in our knowledge of portal hypertension; and iii) future directions.
Keywords: ACE2, angiogenesis-converting enzyme 2; ACLF, acute-on-chronic liver failure; AT1R, angiotensin II type I receptor; CCL2, chemokine (C-C motif) ligand 2; CCl4, carbon tetrachloride; CLD, chronic liver disease; CSPH, clinically significant portal hypertension; Dll4, delta like canonical Notch ligand 4; ECM, extracellular matrix; EUS, endoscopic ultrasound; FXR; FXR, farnesoid X receptor; HCC, hepatocellular carcinoma; HRS, hepatorenal syndrome; HSC; HSCs, hepatic stellate cells; HVPG, hepatic venous pressure gradient; Hsp90, heat shock protein 90; JAK2, Janus kinase 2; KO, knockout; LSEC; LSEC, liver sinusoidal endothelial cells; MLCP, myosin light-chain phosphatase; NET, neutrophil extracellular trap; NO; NO, nitric oxide; NSBB; NSBBs, non-selective beta blockers; PDE, phosphodiesterase; PDGF, platelet-derived growth factor; PIGF, placental growth factor; PKG, cGMP-dependent protein kinase; Rho-kinase; TIPS; TIPS, transjugular intrahepatic portosystemic shunt; VCAM1, vascular cell adhesion molecule 1; VEGF; VEGF, vascular endothelial growth factor; angiogenesis; eNOS, endothelial nitric oxide synthase; fibrosis; liver stiffness; statins; β-Arr2, β-arrestin 2; β1-AR, β1-adrenergic receptor; β2-AR, β2-adrenergic receptor.
© 2021 The Authors.
Conflict of interest statement
Jonel Trebicka has received speaking and/or consulting fees from Gore, Bayer, Alexion, MSD, Gilead, Intercept, Norgine, Grifols, Versantis, and Martin Pharmaceutical. Please refer to the accompanying ICMJE disclosure forms for further details.
Figures



Similar articles
-
Where does TIPS fit in the management of patients with cirrhosis?JHEP Rep. 2020 May 23;2(4):100122. doi: 10.1016/j.jhepr.2020.100122. eCollection 2020 Aug. JHEP Rep. 2020. PMID: 32671331 Free PMC article. Review.
-
Pathophysiology and a Rational Basis of Therapy.Dig Dis. 2015;33(4):508-14. doi: 10.1159/000374099. Epub 2015 Jul 6. Dig Dis. 2015. PMID: 26159267
-
Portal Vein Thrombosis in Cirrhosis.J Clin Exp Hepatol. 2022 May-Jun;12(3):965-979. doi: 10.1016/j.jceh.2021.11.003. Epub 2021 Nov 22. J Clin Exp Hepatol. 2022. PMID: 35677518 Free PMC article. Review.
-
The FXR agonist PX20606 ameliorates portal hypertension by targeting vascular remodelling and sinusoidal dysfunction.J Hepatol. 2017 Apr;66(4):724-733. doi: 10.1016/j.jhep.2016.12.005. Epub 2016 Dec 18. J Hepatol. 2017. PMID: 27993716
-
Role of estrogen receptor β selective agonist in ameliorating portal hypertension in rats with CCl4-induced liver cirrhosis.World J Gastroenterol. 2016 May 14;22(18):4484-500. doi: 10.3748/wjg.v22.i18.4484. World J Gastroenterol. 2016. PMID: 27182159 Free PMC article.
Cited by
-
Response to: "Anticoagulation is not associated with an increased risk of variceal bleeding under systemic therapy for advanced HCC".JHEP Rep. 2024 Jun 17;6(8):101146. doi: 10.1016/j.jhepr.2024.101146. eCollection 2024 Aug. JHEP Rep. 2024. PMID: 39105182 Free PMC article. No abstract available.
-
Liver Function-How to Screen and to Diagnose: Insights from Personal Experiences, Controlled Clinical Studies and Future Perspectives.J Pers Med. 2022 Oct 5;12(10):1657. doi: 10.3390/jpm12101657. J Pers Med. 2022. PMID: 36294796 Free PMC article. Review.
-
Liver sinusoidal endothelial cells as potential drivers of liver fibrosis (Review).Mol Med Rep. 2024 Mar;29(3):40. doi: 10.3892/mmr.2024.13164. Epub 2024 Jan 19. Mol Med Rep. 2024. PMID: 38240102 Free PMC article.
-
Beta-blockers in patients with liver cirrhosis: Pragmatism or perfection?Front Med (Lausanne). 2023 Jan 9;9:1100966. doi: 10.3389/fmed.2022.1100966. eCollection 2022. Front Med (Lausanne). 2023. PMID: 36743678 Free PMC article. Review.
-
How non-alcoholic fatty liver disease and cirrhosis affect the heart.Hepatol Int. 2023 Dec;17(6):1333-1349. doi: 10.1007/s12072-023-10590-1. Epub 2023 Sep 28. Hepatol Int. 2023. PMID: 37770804 Review.
References
-
- Iwakiri Y., Groszmann R.J. The hyperdynamic circulation of chronic liver diseases: from the patient to the molecule. Hepatology. 2006;43:S121–S131. - PubMed
-
- Hennenberg M., Trebicka J., Sauerbruch T., Heller J. Mechanisms of extrahepatic vasodilation in portal hypertension. Gut. 2008;57:1300–1314. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous